AlphAIAlphAI — Financial news for AI agents
investing.comNOV 41 min read$BCRX

BioCryst earnings beat by $0.05, revenue topped estimates

BioCryst (BCRX) reported Q3 EPS of $0.14, beating estimates by $0.05, with revenue of $180.3M, exceeding expectations of $165.37M. The company guided FY 2026 revenue to $715M-$730M, above the consensus of $710.1M. BCRX stock is down 8.64% over 3 months but up 19.53% year-over-year.

Original reporting
investing.com
Published Nov 4, 2026, 12:21 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$BCRX
Bullish
high confidence
Mentioned
$BCRX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BCRXBullishMed
01

Why it matters

The beat may attract short‑term buying, but the modest scale limits broader market impact.

02

Market read

Earnings surprise provides a short‑term trading edge for BCRX; broader market effect is minimal.

03

What to watch

Potential upcoming regulatory or clinical trial outcomes could dominate price action.

Relevance 7/10Novelty 7/10Timing: after-hours today

Background

BioCryst is a small‑cap biotech that recently announced a modest earnings beat and raised its revenue outlook.

Company-level read

Ticker impact

$BCRXBullishHigh confidence
Context

BioCryst reported Q3 EPS $0.140 beating estimate by $0.05 and raised FY2026 revenue guidance to $715‑$730M.

Expected impact

likely modest upside as market prices in the beat and raised outlook

Evidence & confidence

Fresh earnings numbers and guidance are new information that can move the stock in the near term.

Market effects

Sector

Biotech sector may see slight lift as a peer demonstrates earnings resilience.

Regional

U.S. small‑cap biotech investors could adjust positions.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

If the beat is already priced in, the stock could face a pull‑back.

Key entities

  • Company
    BioCryst Pharmaceuticals

    Issuer of the earnings report.

Read at source← All news

StoryBioCryst posts Q3 earnings beat and raises full-year revenue outlook

Also covered by

1 outlet

Related articles

NOV 4
$BCRXMedAI 8/10

BioCryst (BCRX) Q3 2026 Earnings Call Transcript

BioCryst (BCRX) reported Q3 2026 earnings, highlighting growth in ORLADEYO pellet usage among children and a transition to CareMed as their sole pharmacy partner. The company expects to announce top-line data for navenibart in Q3 2027 and is on track to share early clinical data for BCX1771 by year-end. Revenue was $174.8 million, with ORLADEYO revenue increasing 20% year-over-year. The company anticipates continued revenue growth and cost savings in 2027.

finance.yahoo.com7 min
NOV 4
$BCRXHighAI 8/10

BioCryst Q3 2026 slides: HAE portfolio drives 70% profit jump

BioCryst Pharmaceuticals (BCRX) reported Q3 2026 non-GAAP operating profit of $87M, up 70% YoY, driven by ORLADEYO revenue of $175M. The company raised full-year 2026 revenue guidance to $715M-$730M. ORLADEYO showed 91% reduction in monthly attack rate for HAE patients. Navenibart, a potential second HAE treatment, is in Phase 3 trials with data expected in Q3 2027. BioCryst also highlighted its pipeline, including BCX17725 for Netherton syndrome.

investing.com3 min
NOV 4
$BCRXHighAI 8/10

BioCryst Pharmaceuticals Q3 Earnings Call Highlights

BioCryst Pharmaceuticals reported Q3 non-GAAP net income of $71M, up from last year. The company launched ORLADEYO pellets for children and plans to introduce a 150-mg pellet formulation. Pediatric uptake is ahead of expectations. BioCryst maintained 2026 ORLADEYO revenue guidance of $625M-$645M but raised total revenue guidance to $715M-$730M. The company is also progressing with its navenibart trial for HAE and BCX17725 study for Netherton syndrome.

finance.yahoo.com2 min
NOV 4
$BCRXMedAI 8/10

BioCryst: Q3 Earnings Snapshot

BioCryst Pharmaceuticals reported Q3 earnings of $37.9M, or 14 cents per share, exceeding expectations. Revenue was $180.3M, also above forecasts. The company expects full-year revenue between $715M and $730M. Shares are up 10% YTD and 25% over the past year.

finance.yahoo.com2 min
NOV 4
$BCRXHigh

BioCryst Reports Third Quarter 2026 Financial Results

BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 BioCryst Reports Third Quarter 2026 Financial Results — Total net revenue of $180.3 million and ORLADEYO ® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenu

SEC EDGAR 8-K2 min
OCT 22
$BCRXHighAI 9/10

FDA Approves Berotralstat Oral Pellets for Adults, Adolescents With HAE

BioCryst Pharmaceuticals announced FDA approval of a 150 mg oral pellet formulation of berotralstat (Orladeyo) for HAE prophylaxis in patients aged 12+. The approval adds a second dosage form, following prior approvals for capsules and pediatric pellets. BioCryst reports berotralstat is the only targeted oral prophylactic therapy for HAE patients aged 2+.

hcplive.com2 min